The COVID-19 pandemic has revealed a complex interplay between SARS-CoV-2 infection and neuropsychiatric sequelae such as anxiety, depression, cognitive dysfunction (“brain fog”), and post-traumatic stress symptoms. This report summarizes findings from clinical, molecular, and preclinical studies which suggest that the following mechanisms are responsible:
- Direct neuroinvasion and disruption of the blood–brain barrier (BBB), which enable the entry of virus and inflammation into the central nervous system (CNS);
- Dysregulation of neurotransmitters through dopaminergic senescence and cholinergic antagonism; and
- Production of toxins from the gut microbiome that promote neuroinflammation. These pathways intersect at the gut–brain axis, where dysbiosis and bacterial toxins amplify systemic and neuronal inflammation.
Neuroinvasion and impairment of the blood–brain barrier
How SARS-CoV-2 enters the central nervous system
SARS-CoV-2 can enter the CNS via several routes. It can spread through the olfactory nerve, the blood, and infected immune cells[3]. Once the virus has entered the bloodstream, it targets brain microvascular endothelial cells (BMECs) and uses neuropilin-1 (NRP1) receptors on astrocytes and neurons to enter the system[2][3]. In vitro models show that SARS-CoV-2 infection of BMECs increases the expression of matrix metalloproteinase-9 (MMP9), which degrades collagen IV in the basement membrane and weakens BBB integrity[3][13]. This transcellular penetration bypasses tight-junction damage but nonetheless allows viral particles and inflammatory mediators to enter the brain parenchyma[3][12].
Consequences of BBB disruption
Postmortem studies of COVID-19 patients show astrogliosis, microgliosis, and infiltration of immune cells into brain regions critical for mood regulation and cognition[2]. The weakened BBB facilitates the influx of proinflammatory cytokines (e.g., IL-6, TNF-α) and bacterial metabolites, which exacerbates neuroinflammation[5][12]. For example, an elevated monokine induced by gamma interferon (MIG/CXCL9) correlates with depressive symptoms in patients with long COVID, probably through IFN-γ-mediated neurotoxicity[5][11].
Neurotransmitter dysregulation and neuronal senescence
Impairment of the dopaminergic system
SARS-CoV-2 exhibits a tropism for dopamine neurons, which express ACE2 and NRP1 receptors[10]. The infection triggers cellular senescence in dopaminergic neurons, characterized by upregulated p16 and p21 markers and reduced tyrosine hydroxylase activity[10]. This senescence pathway disrupts dopamine synthesis and release and contributes to apathy, anhedonia, and motor deficits resembling parkinsonism[10]. Transcriptional profiling of infected neurons reveals inflammatory gene signatures (e.g., IL-1β, CXCL10) that persist in autopsy samples, suggesting chronic neuronal dysfunction[10].
Cholinergic signaling disruption
Toxin-like peptides homologous to conotoxins, identified in plasma and stool samples of COVID-19 patients, act as competitive antagonists at nicotinic acetylcholine receptors (nAChRs)[4][7][9]. These peptides, possibly produced by gut bacteria under viral influence, inhibit acetylcholine signaling, leading to hyposmia, cognitive slowing, and autonomic dysfunction[7][13]. Computational modeling suggests that the spike protein regions of SARS-CoV-2 share structural motifs with superantigens such as staphylococcal enterotoxins, which enable aberrant T-cell activation and cytokine-driven suppression of the cholinergic anti-inflammatory pathways[11][16].
Gut microbiome dysbiosis and toxin production
Bacterial toxin-like peptides in long-COVID studies
Longitudinal studies have detected toxin-like peptides (e.g., phospholipase A2, zinc metalloproteinases) in the gut microbiome of COVID-19 patients months after viral shedding[4][6][16]. These peptides, which resemble neurotoxins of Clostridium and Bacteroides species, correlate with persistent psychiatric symptoms[6][13]. In vitro, SARS-CoV-2 infection leads to an upregulation of bacterial toxin production that persists even when viral RNA is no longer detectable[6][16].
Dysregulation of the gut–brain axis
COVID-19-induced gut dysbiosis reduces short-chain fatty acid (SCFA)-producing bacteria (e.g., Faecalibacterium), which impairs anti-inflammatory signaling and ACE2-mediated amino acid transport[12][13]. At the same time, pathobionts such as Mitsuokella and Enterococcus citroniae proliferate and release metabolic products that increase gut permeability and systemic inflammation[8][12]. Elevated circulating lipopolysaccharide (LPS) and β-glucans activate microglia via TLR4/Dectin-1 and amplify neuroinflammation and depressive behaviors[14][16].
Systemic inflammation and neuroimmune crosstalk
Cytokine storm and neuropsychiatric consequences
Severe COVID-19 infections trigger a cytokine storm characterized by elevations in IL-6, IL-1β, and TNF-α. These cytokines cross the BBB and alter neuronal excitability[5][11]. Postmortem brain samples show upregulated NLRP3 inflammasomes in microglia, which promote pyroptosis and synaptic loss in the prefrontal cortex[2][5]. Chronic inflammation also leads to a depletion of tetrahydrobiopterin (BH4), a cofactor for dopamine and serotonin synthesis, establishing a link between the rise in cytokines and monoamine deficiency[5][14].
Superantigen-like peptides and autoimmunity
A spike peptide derived from SARS-CoV-2 (P3) shows homology with bacterial superantigens and binds to MHC class II and TCR Vβ chains to activate 25–40% of CD4+/CD8+ T cells[11]. This aberrant activation leads to an increase in IFN-γ and granzyme B, sustaining neuroinflammation and the production of autoantibodies against neuronal targets (e.g., NMDA receptors)[11][15]. Cross-reactivity with commensal bacteria (e.g., E. faecalis) may further amplify the autoimmune responses[15].
Outlook
Addressing these mechanisms requires integrated therapies that target viral persistence, microbiome balance, and neuroimmune crosstalk. Future research must focus on longitudinal studies to decipher the temporal dynamics of these interactions and to validate combinatorial treatments for long COVID.
